Abstracts tagged "pregnancy"

Abstract Number: 1464 • ACR Convergence 2021
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Mala Masson¹, Colin Phoon¹, Elena Sinkovskaya², Lisa Howley³, Ruben Acherman⁴, Majd Makhoul⁵, Nelangi Pinto⁶, Miao Chang¹, Robert Clancy⁷, Bailey Drewes⁸, Bettina Cuneo⁹ and Jill Buyon⁷, ¹NYU Langone Health, New York, NY, ²East Virginia Medical School, Norfolk, ³Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, ⁴Sunrise Children's Hospital, Las Vegas, NV, ⁵UK Kentucky Children's Hospital, Lexington, KY, ⁶University of Utah, Salt Lake City, UT, ⁷NYU Grossman School of Medicine, New York, NY, ⁸CU Anschutz Medical Campus, Aurora, ⁹Children's Hospital Colorado, Aurora, CO
Background/Purpose: Congenital Heart Block (CHB) complicates 2% of anti-Ro/SSA antibody positive pregnancies and carries substantial perinatal morbidity and mortality. Almost all survivors require lifelong pacing.…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 1465 • ACR Convergence 2021
Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States
Yumeko Kawano¹, Kathleen Kolstad², Shufeng Li¹, Julia Simard³ and Lorinda Chung¹, ¹Stanford University, Palo Alto, CA, ²University of California Los Angeles, Santa Barbara, CA, ³Stanford School of Medicine, Stanford, CA
Background/Purpose: Autoimmune connective tissue diseases disproportionately affect women of childbearing age. Systemic sclerosis (SSc) is associated with increased risk of adverse pregnancy outcomes (APO). However,…
Abstract Number: 1730 • ACR Convergence 2021
Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS
Anja Weiß¹, Christina Bungartz¹, Jutta Richter², Susanna Späthling-Mestekemper³, Xenofon Baraliakos⁴, Peer Aries⁵, Rebecca Fischer-Betz⁶ and Anja Strangfeld⁷, ¹DRFZ, Berlin, Germany, ²Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ³Rheumapraxis München, München, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁵Rheumatologie in Hamburg, Hamburg, Germany, ⁶Uniklinik Dsseldorf, Dsseldorf, Germany, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: SpA is a severe chronic inflammatory disease, which affects quality of life and functional status. It frequently occurs in women of childbearing age. Active…
Abstract Number: 1466 • ACR Convergence 2021
Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls
April Barnado, Janie Hubbard, Sarah Green and Sarah Osmundson, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Studies show increased risks of adverse pregnancy outcomes in SLE patients. Few studies have investigated postpartum outcomes in these patients. Using a large, de-identified…
Abstract Number: 1745 • ACR Convergence 2021
Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis
Saadia Ali¹, Shirish Sangle², Maha Al Falah³ and David D'Cruz⁴, ¹Guys and St Thomas' Hospital NHS Trust, Epsom, United Kingdom, ²Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ³Guys and St Thomas' Hospital NHS Trust, Saudi Arabia, United Arab Emirates, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: Mycophenolate Mofetil is not recommended in pregnancy due to teratogenic effects. A previous small prospective study found that switching from MMF to AZA rarely…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Julianna Sabo¹, Namrata Singh², Deborah Crane¹, David Doody³, Melissa Schiff⁴ and Beth Mueller⁵, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴University of Washington, University of New Mexico, Seattle, WA, ⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 1716 • ACR Convergence 2021
Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center
Shruti Chandramouli¹, Carolina Alvarez², R. Gina Silverstein³ and Saira Sheikh⁴, ¹Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Department of Obstetrics & Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, who have an increased risk of pregnancy complications such as preterm labor and preeclampsia,…
Abstract Number: 1249 • ACR Convergence 2020
The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
Eman Satti¹, Nawal Hadwan¹, Hadil Ashour¹, Rawan Saleh¹, Fiaz Alam¹, Omar Alsaed¹ and Samar Al Emadi¹, ¹Hamad medical corporation, DOHA, Qatar
Background/Purpose: Anti-Ro antibody positivity is linked to adverse fetal outcomes like congenital heart block CHB (2%) and neonatal lupus. The incidence of CHB increases to…
Abstract Number: 1770 • ACR Convergence 2020
Lupus Low Disease Activity State Protects Against Pre-Term Birth
Michelle Petri¹, Jessica Li² and Daniel Goldman³, ¹Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus low disease activity state (LLDAS) (Ann Rheum Dis. 2016;75:1615–21.) combine both low disease activity (SLEDAI score of ≤4, PGA >=1 no flare, no…
Abstract Number: 1257 • ACR Convergence 2020
Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Sofia Gernaat¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Stanford Medicine, Stanford, CA, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Increased insulin resistance is pivotal in the development of gestational diabetes mellitus (GDM). Women with SLE may be at higher risk of GDM due…
Abstract Number: 1771 • ACR Convergence 2020
Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
Sabrina Hamroun¹, Aghilès Hamroun², Jean-Joël Bigna³, Frauke Foerger⁴, Edem Allado⁵ and Anna Molto¹, ¹Rheumatology Department, Cochin Hospital, Paris, Paris, France, ²Lille University, Faculty of Medicine, Lille, France, Lille, France, ³School of Public Health, Faculty of Medicine, University of Paris Sud XI, Le Kremlin-Bicêtre, France, Paris, France, ⁴University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, ⁵Rheumatology Department, University Hospital of Nancy, France, Nancy, France
Background/Purpose: Women with spondyloarthritis (SpA) are often affected by the disease during their reproductive years1. However, little is known about the impact of the disease…
Abstract Number: 1323 • ACR Convergence 2020
Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis
Sinead Maguire¹, Tom O'Dwyer², Fiona Wilson³, David Mockler³ and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Independent Researcher, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis affecting the sacroiliac joints and the spine. Although this chronic condition affects a wide range of ages,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].